Cargando…
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various cancers. These drugs are associated with profound, durable responses in a subset of patients with advanced cancers. Unfortunately, in addition to individuals whose tumors show resistance, there is a m...
Autores principales: | Adashek, Jacob J., Kato, Shumei, Ferrara, Roberto, Lo Russo, Giuseppe, Kurzrock, Razelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011624/ https://www.ncbi.nlm.nih.gov/pubmed/32043794 http://dx.doi.org/10.1634/theoncologist.2019-0636 |
Ejemplares similares
-
Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
por: Adashek, Jacob J., et al.
Publicado: (2019) -
Lessons From the Development of the Immune Checkpoint Inhibitors in
Oncology
por: Jardim, Denis L., et al.
Publicado: (2018) -
Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022) -
Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020) -
The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)